Bio-Techne Corporation (TECH) SEC Filings & Earnings Calls

Regulatory approvals still pending; deal may not close.

“subject to satisfaction of customary closing conditions, including remaining regulatory approvals”

Litigation could delay or derail the pending merger with Merck KGaA.

“Lawsuit seeks an order enjoining the shareholder vote on the Merger”

Tariff impact on costs

“Collectively, these tariffs have increased and will continue to increase the cost to us of supplies and components we import, as well as our cost to serve certain markets, which in turn will require us to bear significant increased costs to do business, and/or implement surcharges, and/or increase the price of certain of our products.” · word for word

Pending merger execution risk

“Consummation of the Merger is subject to customary closing conditions, including: (i) the approval of the Merger Agreement... (ii) the expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976” · word for word

Wilson Wolf future cash obligation

“The second option payment of approximately $1 billion plus potential contingent consideration is forecasted to occur between fiscal 2027 and fiscal 2028.” · word for word

Margin pressure from product mix

“Fiscal 2026 consolidated adjusted gross margin was impacted by unfavorable product mix when compared to the prior period.” · word for word

Pending acquisition introduces execution risk and potential regulatory hurdles.

“Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash.” · word for word

Protein Sciences segment operating margin declined 160 bps YoY in Q4 and 150 bps for full year due to unfavorable volume and product mix.

“The segment’s operating margin decreased primarily due to unfavorable volume and product mix.” · word for word

Transaction subject to shareholder and regulatory approvals; may not close.

“Merger Agreement conditions; forward-looking statements caution about completion risks.”

Transaction subject to approvals and other risks; may not close.

“Forward-looking statements caution about completion risks.”

Continued lag in emerging biotech spending may persist, pressuring revenue growth

“offset by a continued lag in spending by emerging biotech” · word for word

Unfavorable product mix impacting margins

“Adjusted operating margin was unfavorably impacted by volume and product mix” · word for word

Protein Sciences Demand Weakness

“Organic revenue for the segment decreased 4% in the quarter ended March 31, 2026.” · word for word

Gross Margin Pressure from Product Mix

“Fluctuations in consolidated gross margin and adjusted gross margin, as a percentage of sales, have primarily resulted from changes in product mix.” · word for word

Wilson Wolf Acquisition Obligation

“The second option payment of approximately $1 billion plus potential contingent consideration is forecasted to occur between fiscal 2026 and fiscal 2028.” · word for word

Restructuring execution risk

“Restructuring plans to recover operating margins and optimize global manufacturing; charges of $3.3M in H1”

Legal/arbitration overhang

“Arbitration with former CEO resolved with $37.2M payment; other litigation may have material adverse impact”

Revenue flat YoY; Diagnostics segment declined 4% due to divestiture; unfavorable product mix.

“Revenue flat; Diagnostics segment -4%; unfavorable product mix”

Restructuring execution risk

“Restructuring and restructuring-related costs $7,511”

Revenue decline in core segments

“Net sales $286,555 vs $289,458 in prior year quarter”

Emerging biotech funding headwinds may continue to pressure demand.

“Funding headwinds persisted for emerging biotech companies.” · word for word

GMP proteins order timing headwinds from customer Fast Track Designations could impact near-term revenue.

“These advancements have resulted in short- and intermediate-term order timing headwinds for our GMP proteins business.” · word for word